Loading...

Lucid Diagnostics Inc.

LUCDNASDAQ
Healthcare
Medical - Devices
$1.15
$0.00(0.00%)

Lucid Diagnostics Inc. (LUCD) Stock Overview

Explore Lucid Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.3/100

Key Financials

Market Cap119M
P/E Ratio-0.00
EPS (TTM)$-1.17
ROE26.96%
Fundamental Analysis

AI Price Forecasts

1 Week$1.43
1 Month$1.34
3 Months$1.68
1 Year Target$0.65

LUCD Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Lucid Diagnostics Inc. (LUCD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.65.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 119M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
79.00%
79.00%
Profit Growth
$-524.05
13.55%
EPS Growth
$-524.05
40.48%
Operating Margin
-1506.27%
5.01%
ROE
2695.90%
13.55%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$2.00
Average$2.25
High$2.50

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

CEO

Lishan Aklog

Employees

72

Headquarters

One Grand Central Place, New York City, NY

Founded

2021

Frequently Asked Questions

;